OncoCyte Corporation (AMEX:OCX) headquartered in Alameda, will host a conference call for the investment community to discuss the 3Q20 earnings result on 12th November 2020 at 4:30 PM Eastern Time.
Those interested in listening to the conference call live via the Internet can visit www.oncocyte.com
Individuals interested in participating in the audio call may dial the listen only number(s) 877-407-9716 Toll Free or 201-493-6779 (International), and the passcode is 13709425
Earnings Expectation
OncoCyte Corporation is set to announce third quarter earning results on Thursday 12th November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, OCX to report 3Q20 loss of $ 0.09 per share from revenue of $ 0.37 million. For the full year, analysts anticipate top line of $ 1.35 million, while looking forward to loss of $ 0.45 per share bottom line.
OncoCyte Corporation engages in the development and commercialization of non-invasive blood-based diagnostic tests for the early detection of cancer. The company is developing DetermaVu, a non-invasive molecular lung cancer confirmatory diagnostic that is administered to patients as a blood test. It also develops diagnostic tests based on liquid biopsies for detecting breast cancer.
